Tamsulosin Hydrochloride Capsule
Product Images NDC 43063-725

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 43063-725). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063725 Label (43063725)

The label for Tamsulosin Hydrochloride capsules shows a strength of 0.4 mg with 90 capsules per container. The product is labeled by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. The label includes the NDC 43063-725-90, lot number C22F40, and expiration date of 12/2023. It also contains dosage instructions in English and Spanish and a barcode.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride (0.4 mg capsules) over time up to 36 hours. The graph compares concentrations under fasted and fed conditions, with plasma concentration (ng/mL) on the y-axis and time (hours) on the x-axis. The fasted condition shows a higher and earlier peak compared to the fed condition.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean change on the y-axis and duration of treatment in weeks on the x-axis. The graph compares three treatments: 0.8 mg, 0.4 mg of Tamsulosin Hydrochloride, and placebo, with sample sizes noted per time point. Lines indicate symptom score changes over up to 13 weeks and last observation carried forward (LOCF) data.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean change over a 13-week treatment duration. The x-axis represents weeks, and the y-axis shows mean change values ranging from 0 to -11. Three treatment groups are plotted: 0.8 mg, 0.4 mg, and placebo. Both the 0.8 mg and 0.4 mg groups show greater negative mean changes in symptom scores compared to placebo, indicating symptom improvement over time.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in mL/sec over treatment duration in weeks for three groups: 0.8 mg treatment (circles), 0.4 mg treatment (triangles), and placebo (squares). The graph tracks changes from baseline through weeks 0 to 13 and last observation carried forward (LOCF), with sample sizes noted at each time point.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in urine flow over weeks of treatment. The x-axis represents duration of treatment in weeks, and the y-axis represents mean change in peak urine flow rate in mL/sec. The graph compares three groups: 0.8 mg dose, 0.4 mg dose, and placebo, each represented by different line styles and markers, depicting trends over a 13-week period plus a last observation carry forward (LOCF) time point.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure diagram of Tamsulosin Hydrochloride showing its molecular components and bonds, including aromatic rings, methoxy groups, and hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.